Journal article
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia
Kidney international, v 82(11), pp 1215-1222
01 Dec 2012
PMID: 22932122
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Hyponatremia is the most common electrolyte disorder in clinical practice. Its incidence increases with age and it is associated with increased morbidity and mortality. Recently, the vaptans, antagonists of the arginine vasopressin pathway, have shown promise for safe treatment of hyponatremia. Here we evaluated the efficacy, safety, and tolerability of oral lixivaptan, a selective vasopressin V2-receptor antagonist, for treatment of nonhospitalized individuals with euvolemic hyponatremia (sodium less than 135mmol/l) in a multicenter, randomized, double-blind, placebo-controlled, phase III study. About half of the 206 patients were elderly in a chronic care setting. Of these patients, 52 were given a placebo and 154 were given 25–100mg per day lixivaptan, titrated based on the daily serum sodium measurements. Compared with placebo (0.8mmol/l), the serum sodium concentration significantly increased by 3.2mmol/l from baseline to day 7 (primary efficacy endpoint) with lixivaptan treatment. A significantly greater proportion of patients that received lixivaptan achieved normal serum sodium (39.4%) by day 7 relative to placebo (12.2%). Overall, lixivaptan was considered safe and well-tolerated. Thus, oral lixivaptan can be safely initiated in the outpatient setting and effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.
Metrics
Details
- Title
- Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia
- Creators
- William T. Abraham - The Ohio State UniversityGuy Decaux - Erasmus HospitalRichard C. Josiassen - Drexel UniversityYoram Yagil - Barzilai Medical CenterNelson Kopyt - Lehigh Valley Hospital-PoconoHemant P. Thacker - Bhatia HospitalMassimo Mannelli - University of FlorenceDaniel G. Bichet - Hôpital du Sacré-Cœur de MontréalCesare Orlandi - Cardiokine Biopharma, Inc., Philadelphia, Pennsylvania, USAfor the HARMONY Study GroupHARMONY Study Grp
- Publication Details
- Kidney international, v 82(11), pp 1215-1222
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Psychiatry
- Web of Science ID
- WOS:000311156300011
- Scopus ID
- 2-s2.0-84869238944
- Other Identifier
- 991019167890704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Urology & Nephrology